Last reviewed · How we verify
China-approved Bevacizumab
Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), inhibiting tumor angiogenesis and reducing blood supply to cancer cells.
Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), inhibiting tumor angiogenesis and reducing blood supply to cancer cells. Used for Metastatic colorectal cancer, Metastatic non-small cell lung cancer, Metastatic breast cancer.
At a glance
| Generic name | China-approved Bevacizumab |
|---|---|
| Sponsor | Zhejiang Teruisi Pharmaceutical Inc. |
| Drug class | VEGF inhibitor (monoclonal antibody) |
| Target | VEGF (Vascular Endothelial Growth Factor) |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Bevacizumab binds to circulating VEGF, preventing its interaction with VEGF receptors on endothelial cells. This inhibits the formation of new blood vessels that tumors require for growth and metastasis. By starving tumors of their blood supply, bevacizumab slows tumor progression and can enhance the efficacy of chemotherapy.
Approved indications
- Metastatic colorectal cancer
- Metastatic non-small cell lung cancer
- Metastatic breast cancer
- Recurrent glioblastoma
- Metastatic renal cell carcinoma
Common side effects
- Hypertension
- Proteinuria
- Hemorrhage
- Thromboembolism
- Gastrointestinal perforation
- Wound healing complications
- Fatigue
Key clinical trials
- A Study Assessing the Interchangeability Between TRS003 and Bevacizumab® For CRC (PHASE3)
- A Study to Compare the Similarity in Efficacy and Safety Between TRS003 and China-approved Bevacizumab® in NSCLC (PHASE3)
- A Study to Compare Pharmacokinetic and Safety of TRS003 to China-approved Bevacizumab and US-licensed Avastin® (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- China-approved Bevacizumab CI brief — competitive landscape report
- China-approved Bevacizumab updates RSS · CI watch RSS
- Zhejiang Teruisi Pharmaceutical Inc. portfolio CI